10 October 2013 6 3K Report

In some ligand/enzyme systems I have found very good correlation between the in silico docking of ligands in the active-site of an enzyme (i.e., calculated interaction energy score) and the activity of ligands in an in vitro enzyme assay and a cell based assay.

However, recently I have seen disjunction between those three assays. While the most potent drugs in silico (based on interaction energy score) were still the most potent in vitro and in cell culture, some compounds that have good in silico scores fail completely in an in vitro enzyme assay, but are active in a cell based assay. Obvious issues include the modeling software and force field (I am using a tested software package-Discovery Studio with CFF) and the solubility of the ligands in the in vitro assay.

I was wondering what your experience is in seeing ligands that were modified within a cell, in a cell-based assay, into a more soluble and/or potent drug since that would explain some of my results. Of course the ligands could be hitting targets other than the enzyme I am studying, but the ligands are highly chemically related with only single side-group modifications (i.e., a H3CO- for a HO- at the same position on a ring). Thank you for your feedback.

UPDATE: part of the problem it turns out was that the compounds were not stable to freeze/thaw in 100% DMSO, one freeze/thaw reduced activity, and a second freeze/thaw reduced activity by up to 90%. This affected the in vitro assays, however, the person doing the cell culture assays was not putting the compounds through multiple freeze/thaw cycles. First time I have seen this issue with compounds stored in DMSO.

More Gary S. Laco's questions See All
Similar questions and discussions